Literature DB >> 29848659

Sphingolipids inhibit endosomal recycling of nutrient transporters by inactivating ARF6.

Brendan T Finicle1, Manuel U Ramirez1, Gang Liu1, Elizabeth M Selwan1, Alison N McCracken1, Jingwen Yu1, Yoosun Joo1, Jannett Nguyen1, Kevin Ou1, Saurabh Ghosh Roy1, Victor D Mendoza1, Dania Virginia Corrales1, Aimee L Edinger2.   

Abstract

Endogenous sphingolipids (ceramide) and related synthetic molecules (FTY720, SH-BC-893) reduce nutrient access by decreasing cell surface expression of a subset of nutrient transporter proteins. Here, we report that these sphingolipids disrupt endocytic recycling by inactivating the small GTPase ARF6. Consistent with reported roles for ARF6 in maintaining the tubular recycling endosome, MICAL-L1-positive tubules were lost from sphingolipid-treated cells. We propose that ARF6 inactivation may occur downstream of PP2A activation since: (1) sphingolipids that fail to activate PP2A did not reduce ARF6-GTP levels; (2) a structurally unrelated PP2A activator disrupted tubular recycling endosome morphology and transporter localization; and (3) overexpression of a phosphomimetic mutant of the ARF6 GEF GRP1 prevented nutrient transporter loss. ARF6 inhibition alone was not toxic; however, the ARF6 inhibitors SecinH3 and NAV2729 dramatically enhanced the killing of cancer cells by SH-BC-893 without increasing toxicity to peripheral blood mononuclear cells, suggesting that ARF6 inactivation contributes to the anti-neoplastic actions of sphingolipids. Taken together, these studies provide mechanistic insight into how ceramide and sphingolipid-like molecules limit nutrient access and suppress tumor cell growth and survival.
© 2018. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  ARF6; Endosomal recycling; GRP1; Nutrient transporters; Sphingolipids

Mesh:

Substances:

Year:  2018        PMID: 29848659      PMCID: PMC6031383          DOI: 10.1242/jcs.213314

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  86 in total

Review 1.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 2.  Recycling and EH domain proteins at the synapse.

Authors:  María Luz Montesinos; Manuel Castellano-Muñoz; Pablo García-Junco-Clemente; Rafael Fernández-Chacón
Journal:  Brain Res Brain Res Rev       Date:  2005-09

3.  GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration.

Authors:  Christine Anna Parachoniak; Yi Luo; Jasmine Vanessa Abella; James H Keen; Morag Park
Journal:  Dev Cell       Date:  2011-06-14       Impact factor: 12.270

Review 4.  Clathrin-independent endocytosis: a cargo-centric view.

Authors:  Lymarie Maldonado-Báez; Chad Williamson; Julie G Donaldson
Journal:  Exp Cell Res       Date:  2013-08-13       Impact factor: 3.905

5.  Ceramide-activated protein phosphatase-2A activity in insulin-secreting cells.

Authors:  A Kowluru; S A Metz
Journal:  FEBS Lett       Date:  1997-11-24       Impact factor: 4.124

6.  Ceramide starves cells to death by downregulating nutrient transporter proteins.

Authors:  Garret G Guenther; Eigen R Peralta; Kimberly Romero Rosales; Susan Y Wong; Leah J Siskind; Aimee L Edinger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

Review 7.  All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.

Authors:  Jaya Sangodkar; Caroline C Farrington; Kimberly McClinch; Matthew D Galsky; David B Kastrinsky; Goutham Narla
Journal:  FEBS J       Date:  2015-11-14       Impact factor: 5.542

8.  GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.

Authors:  Masaki Morishige; Shigeru Hashimoto; Eiji Ogawa; Yoshinobu Toda; Hirokazu Kotani; Mayumi Hirose; Shumei Wei; Ari Hashimoto; Atsuko Yamada; Hajime Yano; Yuichi Mazaki; Hiroshi Kodama; Yoshinori Nio; Toshiaki Manabe; Hiromi Wada; Hidenori Kobayashi; Hisataka Sabe
Journal:  Nat Cell Biol       Date:  2007-12-16       Impact factor: 28.824

9.  ARF6-JIP3/4 regulate endosomal tubules for MT1-MMP exocytosis in cancer invasion.

Authors:  Valentina Marchesin; Antonio Castro-Castro; Catalina Lodillinsky; Alessia Castagnino; Joanna Cyrta; Hélène Bonsang-Kitzis; Laetitia Fuhrmann; Marie Irondelle; Elvira Infante; Guillaume Montagnac; Fabien Reyal; Anne Vincent-Salomon; Philippe Chavrier
Journal:  J Cell Biol       Date:  2015-10-26       Impact factor: 10.539

10.  Overexpression of the ARF1 exchange factor ARNO inhibits the early secretory pathway and causes the disassembly of the Golgi complex.

Authors:  S Monier; P Chardin; S Robineau; B Goud
Journal:  J Cell Sci       Date:  1998-11       Impact factor: 5.285

View more
  10 in total

Review 1.  The Lard Works in Mysterious Ways: Ceramides in Nutrition-Linked Chronic Disease.

Authors:  Rebekah J Nicholson; Marie K Norris; Annelise M Poss; William L Holland; Scott A Summers
Journal:  Annu Rev Nutr       Date:  2022-05-18       Impact factor: 9.323

2.  Kir2.1-mediated membrane potential promotes nutrient acquisition and inflammation through regulation of nutrient transporters.

Authors:  Weiwei Yu; Zhen Wang; Xiafei Yu; Yonghui Zhao; Zili Xie; Kailian Zhang; Zhexu Chi; Sheng Chen; Ting Xu; Danlu Jiang; Xingchen Guo; Mobai Li; Jian Zhang; Hui Fang; Dehang Yang; Yuxian Guo; Xuyan Yang; Xue Zhang; Yingliang Wu; Wei Yang; Di Wang
Journal:  Nat Commun       Date:  2022-06-21       Impact factor: 17.694

3.  Synthetic Sphingolipids with 1,2-Pyridazine Appendages Improve Antiproliferative Activity in Human Cancer Cell Lines.

Authors:  Sylvestre P J T Bachollet; Vito Vece; Alison N McCracken; Brendan T Finicle; Elizabeth Selwan; Nadine Ben Romdhane; Amogha Dahal; Cuauhtemoc Ramirez; Aimee L Edinger; Stephen Hanessian
Journal:  ACS Med Chem Lett       Date:  2020-02-12       Impact factor: 4.632

4.  Avicin G is a potent sphingomyelinase inhibitor and blocks oncogenic K- and H-Ras signaling.

Authors:  Christian M Garrido; Karen M Henkels; Kristen M Rehl; Hong Liang; Yong Zhou; Jordan U Gutterman; Kwang-Jin Cho
Journal:  Sci Rep       Date:  2020-06-04       Impact factor: 4.379

5.  FTY720 induces non-canonical phosphatidylserine externalization and cell death in acute myeloid leukemia.

Authors:  Megan M Young; Van Bui; Chong Chen; Hong-Gang Wang
Journal:  Cell Death Dis       Date:  2019-11-07       Impact factor: 8.469

Review 6.  Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease.

Authors:  Stanislav Kotlyarov; Aleksei Bulgakov
Journal:  Cells       Date:  2021-11-01       Impact factor: 6.600

7.  Dynamic Phosphoproteomics Uncovers Signaling Pathways Modulated by Anti-oncogenic Sphingolipid Analogs.

Authors:  Peter Kubiniok; Brendan T Finicle; Fanny Piffaretti; Alison N McCracken; Michael Perryman; Stephen Hanessian; Aimee L Edinger; Pierre Thibault
Journal:  Mol Cell Proteomics       Date:  2018-11-27       Impact factor: 5.911

Review 8.  Metabolic Messengers: ceramides.

Authors:  Scott A Summers; Bhagirath Chaurasia; William L Holland
Journal:  Nat Metab       Date:  2019-10-24

Review 9.  Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity.

Authors:  Karen M Henkels; Kristen M Rehl; Kwang-Jin Cho
Journal:  Front Mol Biosci       Date:  2021-06-16

10.  Drug-like sphingolipid SH-BC-893 opposes ceramide-induced mitochondrial fission and corrects diet-induced obesity.

Authors:  Vaishali Jayashankar; Elizabeth Selwan; Sarah E Hancock; Amandine Verlande; Maggie O Goodson; Kazumi H Eckenstein; Giedre Milinkeviciute; Brianna M Hoover; Bin Chen; Angela G Fleischman; Karina S Cramer; Stephen Hanessian; Selma Masri; Nigel Turner; Aimee L Edinger
Journal:  EMBO Mol Med       Date:  2021-07-07       Impact factor: 12.137

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.